Read which pharmaceutical companies are addressing the risk of muscle mass loss associated with popular weight loss drugs from Novo (NOVO) and Eli Lilly (LLY).

A pharmacist warns that off-brand Ozempic, Zepbound, and other weight loss products carry undisclosed risks for consumers.

PBMs are putting weight loss drugs, including Wegovy and Zepbound, on their national formularies, but coverage by plans is ...

We recently compiled a list of the 10 Most Promising Growth Stocks According to Hedge Funds. In this article, we are going to ...

Semaglutide — the active ingredient in Ozempic®, Wegovy®, and Rybelsus® — can reduce your appetite and curb food cravings to ...

FDA halts actions on makers of compounded drugs as it reviews decision to remove Eli Lilly's (LLY) weight loss drug ...

If Medicare were to start covering popular weight loss drugs such as Wegovy and Zepbound, it could increase federal spending ...

Weight-loss medications like the popular versions made by Denmark's Novo Nordisk A/S (CSE:NOVOb) and US peer Eli Lilly ...

Eli Lilly anticipates regulatory approval for its weight-loss drug Zepbound in Japan by mid-2025, boosting its global ...

Like many health plans, Lilla’s insurance didn’t cover Wegovy for weight loss use. Out of pocket, a month’s supply came with a price tag of more than $1,300. Even after applying a coupon from the drug ...